Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This research reviewed existing literature to explore treatment options for androgen-dependent diseases, reporting that among prostate cancer therapies analyzed, the drug olaparib as monotherapy resulted in longer survival compared to the combination of apalutamide and abiraterone, though combined treatment efficacy differences were not statistically significant.

This review discusses the challenges in developing combination therapies for urological conditions and notes that regulatory requirements and financial disincentives hinder progress, without presenting new clinical findings.

A new compound may effectively inhibit the enzyme linked to BPH and hair loss.

This study found that use of 5-alpha reductase inhibitors for benign prostatic hyperplasia was not associated with an increased risk of hip fracture in men.

This review discusses the pathological factors and comorbidities associated with androgenetic alopecia and reports no new clinical results, emphasizing the need for improved understanding and treatment in clinical practice.

This study found that patients with BPH who received finasteride before TURP experienced reduced intraoperative blood loss and improved quality of life one month after surgery compared to those who did not.

This study observed that finasteride therapy reduced PSA levels by about 40% over a year in Chinese patients with benign prostatic hyperplasia, with varying effects based on baseline PSA levels.

This study found that early-onset androgenetic alopecia is associated with higher prevalence of metabolic syndrome, atheroma plaques, and urinary symptoms related to prostate growth compared to controls.

This study found that higher baseline expression of SRD5A2 in prostate tissue was associated with a better response to finasteride in men with benign prostatic hyperplasia.

This study detected a significant association between finasteride use and sexual dysfunction, particularly in younger patients with alopecia, suggesting that indication and reporting stimulation may influence the observed signal.

Early hair loss in men could be a sign of non-cancerous prostate enlargement, and treating hair loss early might help prevent prostate issues later.

Hair loss can be an early sign of prostate enlargement.

This article discusses the FDA approval of dutasteride for benign prostatic hypertrophy and explores its potential role in treating androgenetic alopecia but reports no new clinical findings.

Finasteride reduces prostate size and symptoms with few side effects.

This study found that patients on dutasteride had $20.50 lower monthly medical costs compared to those on finasteride.

African plum is linked to treating BPH and has economic benefits.

This study found that methanol extract from Sapium rotundifolium Hemsl. reduced prostate enlargement and related protein expressions in testosterone-induced benign prostatic hyperplasia models in both cells and rats.

The authors concluded that while finasteride 1 mg affects prostate-related pathways, evidence is insufficient to prove clinical benefits for prostate outcomes compared to the established effectiveness of finasteride 5 mg.

This study reports the discovery of LX-38, a new high-affinity non-steroidal antagonist that could provide the therapeutic benefits of current BPH and AGA treatments without the hormonal side effects, utilizing a distinct "Orthogonal T-Stacking" scaffold for binding.

In this retrospective, population-based cohort study, researchers found no significant difference in age-related macular degeneration incidence between BPH patients using 5α-reductase inhibitors and those on tamsulosin, but observed a slight increased risk with dutasteride compared to finasteride.

This study demonstrated that 12 months of 5 mg daily finasteride treatment reduced prostate volume, dihydrotestosterone, and prostate-specific antigen levels, while improving urinary flow rates and symptom scores in benign prostatic hyperplasia patients.

This study found that using gallate-containing formulations like EGCG or tannic acid increased the solubility and controlled release of finasteride in microspheres, enhancing its dermal penetration in pig skin by 10 to 50 times compared to a control.

In this study, significantly fewer men treated with finasteride for moderate to severe BPH symptoms experienced acute urinary retention or required subsequent BPH-related surgery compared to placebo-treated patients.

This study found that LHE may prevent and reverse testosterone-induced prostatic hyperplasia, supporting the traditional use of Kigelia africana for some reproductive system disorders.

Finasteride is beneficial for BPH but requires careful monitoring due to cancer risks.

This study developed and validated a sensitive LC-MS/MS method for quantifying tamsulosin in human serum, achieving high analyte recovery and demonstrating applicability in clinical research for benign prostatic hyperplasia.

This update provides information on new drug approvals but does not offer new clinical research findings.

This review critically examines the current medical management strategies for BPH/LUTS and reports no new experimental results.

Finasteride helps reduce prostate size and symptoms in BPH but is less effective than terazosin and works best for larger prostates.

This review discusses the potential risks of ejaculatory dysfunction associated with both medical and surgical treatments for lower urinary tract symptoms due to benign prostatic hyperplasia and their implications for male fertility, but it reports no new clinical results.